- Film coated oral tablets: 400 mg
- Chewable oral tablets: 25 mg and 100 mg
- Granules for oral suspension: single use packet of 100 mg
- Raltegravir is primarily broken down by UGT1A1 enzymes. Medicines which alter the activity of these enzymes may affect blood levels of raltegravir. For example, rifampin (Rimactane) is known to increase the activity of UGT1A1 enzymes, and consequently reduces the blood levels of raltegravir.
- Patients should avoid taking raltegravir with aluminum or magnesium containing antacids which may reduce blood levels of raltegravir.
PREGNANCY AND BREASTFEEDING SAFETY:
- Use of raltegravir in pregnant women has not been adequately evaluated. Due to the lack of conclusive safety data, raltegravir should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. Raltegravir is classified as FDA pregnancy risk category C.
- Breastfeeding is not recommended while taking raltegravir. To avoid transmitting the HIV-1 virus to the nursing infant, it is not recommended that HIV-1-infected mothers breastfeed their infants. It is not known if raltegravir is excreted into human milk.
- Raltegravir should be stored at room temperature between 20 C to 25 C (68 F to 77 F).
- For best protection the chewable tablets and granules for oral suspension should be stored in the original container.
Quick GuideHIV AIDS Pictures Slideshow: Myths and Facts on Symptoms and Treatments
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.